Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Malibu shines a light on CLINUVELs pioneering work in photomedicine
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Clinuvel Pharmaceuticals has reported data from a Phase II CUV156 study of its melanocortin drug, afamelanotide, in xeroderma pigmentosum (XP) patients.
CLINUVEL Trial Results Show Drug Reduces DNA Damage
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Â Â Â Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...
MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply of ACTH with one of its strategic partners to meet existing global demand, and will be evaluating the potential of NEURACTHEL® for patients with neurological, endocrinological, and degenerative disorders, who lack alternative therapy.